HomeGeneticsGeneCEBPA gene
Back to Gene
CEBPA gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

CEBPA gene

The CEBPA gene encodes a transcription factor that regulates blood cell maturation and acts as a tumor suppressor to prevent uncontrolled cell division.

Normal Function

The CEBPA gene provides instructions for making the CCAAT enhancer-binding protein alpha. This protein is a transcription factor, meaning it attaches to specific regions of DNA to control the activity of certain genes. It is involved in the maturation (differentiation) of certain blood cells and acts as a tumor suppressor, helping to prevent cells from growing and dividing too rapidly.

Health Conditions Related to Genetic Changes

Familial acute myeloid leukemia with mutated CEBPA

Inherited mutations in the CEBPA gene result in a shorter version of the CCAAT enhancer-binding protein alpha. This shortened protein interferes with the tumor suppressor function of the normal protein produced by the second copy of the gene. This disruption leads to the uncontrolled production of abnormal cells characteristic of acute myeloid leukemia.

Most individuals with this condition also acquire a second, somatic mutation in the other copy of the CEBPA gene within their leukemia cells. This second mutation often decreases the protein's DNA-binding ability, further impairing blood cell differentiation.

Cytogenetically normal acute myeloid leukemia

Mutations in the CEBPA gene are found in approximately 18 percent of individuals with cytogenetically normal acute myeloid leukemia (CN-AML). These mutations can be inherited (familial) or non-inherited (sporadic).

  • Shortened protein mutations: Interfere with the tumor suppressor function of normal CCAAT enhancer-binding protein alpha.
  • DNA-binding mutations: Block the protein's ability to bind to DNA, preventing it from regulating gene expression.

In both cases, the impairment of the tumor suppressor function leads to the uncontrolled production of abnormal white blood cells.

Frequently Asked Questions

If multiple family members have AML, especially at a young age, or if there is a pattern of early onset, a genetic counselor can recommend testing for germline CEBPA mutations. A positive result indicates a hereditary predisposition. What are the implications of a germline CEBPA mutation for my own cancer risk?::Individuals with a germline CEBPA mutation have an increased risk of developing AML, often requiring regular blood counts and possibly early intervention if abnormal cells appear. Some clinicians may recommend periodic bone marrow evaluations, though guidelines are evolving. What treatment strategies are preferred for AML patients with CEBPA mutations?::Patients with CEBPA-mutated AML generally respond well to standard induction chemotherapy (e.g., cytarabine plus an anthracycline). They may also benefit from targeted therapies such as FLT3 inhibitors if additional mutations are present. Post‑remission consolidation with high‑dose cytarabine or allogeneic stem‑cell transplant is considered based on risk factors. How does a CEBPA mutation affect the prognosis of AML?::CEBPA mutations, particularly biallelic ones, are associated with a favorable prognosis and higher overall survival rates compared to other AML subtypes. However, the presence of additional adverse mutations can modify this outlook, so comprehensive genomic profiling is recommended.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab

Sök
Om ossVillkor och policyVanliga frågorKontakta oss